These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 22860286)

  • 1. Advances in the development of improved animal-free models for use in breast cancer biomedical research.
    Roberts S; Speirs V
    Biophys Rev; 2017 Aug; 9(4):321-327. PubMed ID: 28748520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?
    Manning J; O'Malley D
    J Muscle Res Cell Motil; 2015 Apr; 36(2):155-67. PubMed ID: 25669899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research from the bedside to the lab bench & back.
    White RA; Silvey M; Logsdon DP
    Mo Med; 2012; 109(3):195-8. PubMed ID: 22860286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models of hereditary hematologic disease.
    Bannerman RM
    Birth Defects Orig Artic Ser; 1974; 10(10):278-85. PubMed ID: 4462638
    [No Abstract]   [Full Text] [Related]  

  • 5. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tracking progress: an update on animal models for Duchenne muscular dystrophy.
    Wells DJ
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29914884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.
    Al-Khalidi R; Panicucci C; Cox P; Chira N; Róg J; Young CNJ; McGeehan RE; Ambati K; Ambati J; Zabłocki K; Gazzerro E; Arkle S; Bruno C; Górecki DC
    Acta Neuropathol Commun; 2018 Apr; 6(1):27. PubMed ID: 29642926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characteristics of dystrophic skeletal muscle: insights from animal models.
    Watchko JF; O'Day TL; Hoffman EP
    J Appl Physiol (1985); 2002 Aug; 93(2):407-17. PubMed ID: 12133845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on iron chelators in thalassemia.
    Neufeld EJ
    Hematology Am Soc Hematol Educ Program; 2010; 2010():451-5. PubMed ID: 21239834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron-chelating therapy for transfusional iron overload.
    Brittenham GM
    N Engl J Med; 2011 Jan; 364(2):146-56. PubMed ID: 21226580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation in erythroid specific transcription factor KLF1 causes Hereditary Spherocytosis in the Nan hemolytic anemia mouse model.
    Heruth DP; Hawkins T; Logsdon DP; Gibson MI; Sokolovsky IV; Nsumu NN; Major SL; Fegley B; Woods GM; Lewing KB; Neville KA; Cornetta K; Peterson KR; White RA
    Genomics; 2010 Nov; 96(5):303-7. PubMed ID: 20691777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
    Kontoghiorghes GJ
    Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
    Kontoghiorghes GJ; Spyrou A; Kolnagou A
    Hemoglobin; 2010 Jun; 34(3):251-64. PubMed ID: 20524815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.